文献速递乳腺癌放疗

早期低危乳腺癌术中放疗的前瞻性观察研究结局

IORT for early-stage, low-risk breast cancer: Outcomes from a prospective, observational study.
PubMed 文献 · Clin Transl Radiat Oncol · 2025-06-22

该前瞻性单中心观察研究纳入464例接受保乳手术的早期低危乳腺癌患者,按TARGIT-A试验实验组方案实施术中放疗并采用更严格入选标准。中位随访45.3个月,全队列5年同侧乳腺复发风险1.7%,仅术中放疗组2.1%,术中放疗联合全乳放疗组1%,5年总生存率97.6%。

要点

  • 全队列5年同侧乳腺复发风险1.7%,仅IORT组2.1%,IORT+WBI组1%。
  • 年龄<50岁与手术切缘近或受累为同侧乳腺复发的独立危险因素。
  • 未报告3-4级毒性事件,84%患者自评美容效果优或良。

核心结论

  • 各组的局部复发率均较低,采用比TARGIT-A试验更严格的入选标准可获得更优的局部控制。
  • 需更长时间随访以确认上述发现。

研究设计与样本

  • 最终464例接受术中放疗,治疗方案复制TARGIT-A试验实验组并采用更严格入选标准及风险适应策略。
  • 主要终点为同侧乳腺复发率,次要终点包括局部无复发生存、无进展生存、总生存及患者自评美容效果。

主要发现

  • 中位随访45.3(范围8-89)个月,全队列估计5年同侧乳腺复发风险为1.7%(95%CI:0.7%-2.8%)。
  • 术中放疗联合全乳放疗队列5年同侧乳腺复发风险为1%(95%CI:0.3%-2.4%),仅术中放疗队列为2.1%(95%CI:0.6%-3.7%),三个亚组间无显著差异。
  • 5年总生存率为97.6%(95%CI:96.0%-99.1%),乳腺癌特异生存率为99.5%(95%CI:98.5%-100%)。
  • 同侧乳腺复发的两个独立显著危险因素为年龄<50岁(HR=0.138,95%CI:0.032-0.597,p=0.008)和手术切缘近或受累(HR=5.8,95%CI:1.5-22.5,p=0.011)。
  • 未报告3-4级毒性事件,84%病例患者自评美容效果为优或良。

关键数值与推荐

  • 术中放疗方案复制TARGIT-A试验实验组,并实施更严格的入选标准及风险适应策略。
  • 全队列5年同侧乳腺复发风险1.7%(95%CI:0.7%-2.8%),术中放疗联合全乳放疗组1%(95%CI:0.3%-2.4%),仅术中放疗组2.1%(95%CI:0.6%-3.7%)。
  • 年龄<50岁(HR=0.138,95%CI:0.032-0.597,p=0.008)和切缘近或受累(HR=5.8,95%CI:1.5-22.5,p=0.011)为同侧乳腺复发的独立危险因素。

临床怎么用

  • 对于早期低危乳腺癌患者,采用比TARGIT-A试验更严格的入选标准实施术中放疗,可获得较低的局部复发率。
  • 年龄<50岁及手术切缘近或受累的患者同侧乳腺复发风险较高,应加强关注。

局限性

  • 为单中心前瞻性观察性研究,随访时间仍较短,需更长时间随访确认结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Treatment of early-stage, low-risk breast cancer (BC) has undergone significant de-escalation during the past years. The TARGIT-A trial provided information on intraoperative radiotherapy (IORT) as a convenient, single-fraction modality. Nevertheless, significant discussion regarding different aspects of the trial continues. This study reports on oncological outcomes in a real-world clinical setting and contributes to the understanding of its optimal indication. METHODS: Five-hundred patients planned for breast-conserving surgery (BCS) were screened for IORT between June 2017 and December 2023, within this prospective, observational, single-center. The treatment protocol replicated the experimental arm of the TARGIT-A trial, implementing stricter inclusion criteria and maintaining a risk-adapted approach. The primary endpoint was ipsilateral breast recurrence rates (IBR). Secondary endpoints included local recurrence-free survival, progression-free survival, overall survival, and patient-reported cosmesis. The Kaplan-Meier method was used to analyze survival and recurrence risk, and risk factors for IBR were assessed through Cox regression analysis. RESULTS: After screening and recruiting, IORT was performed in 464 patients. The median follow-up was 45.3 (8-89) months. The estimated 5-year IBR risk in the entire cohort was 1.7 % (95 % CI: 0.7 %-2.8 %), decreasing to 1 % (95 % CI: 0.3 %-2.4 %) in the IORT + whole breast irradiation (WBI) cohort. In the IORT-only cohort, the risk was 2.1 % (95 % CI: 0.6 %-3.7 %). No significant differences were observed among the three subgroups. The 5-year overall survival and breast cancer-specific survival rates were 97.6 % (95 % CI: 96.0 %-99.1 %) and 99.5 % (95 % CI: 98.5 %-100 %), respectively. Two independent significant risk factors for IBR were identified: age < 50 years (HR = 0.138, 95 % CI: 0.032-0.597, p = 0.008) and close or affected surgical margins (HR = 5.8, 95 % CI: 1.5-22.5, p = 0.011). No grade 3-4 toxicity events were reported. Patient-reported cosmesis was excellent/good in 84 % of cases. CONCLUSIONS: Local recurrence rates were low amongst all groups. Superior control outcomes could be obtained by applying more restrictive criteria than the TARGIT A trial. Longer follow-up is needed to confirm our findings.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Palacios-Eito A, Moreno-Manzanaro MDC, Espinosa-Calvo M, et al. IORT for early-stage, low-risk breast cancer: Outcomes from a prospective, observational study. Clin Transl Radiat Oncol. 2025. PMID: 40656676. doi:10.1016/j.ctro.2025.100998

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。